Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Hotta, K.
Kiura, K.
Takigawa, N.
Tabata, M.
Fujiwara, Y.
Tanimoto, M.
机构：
[1] Okayama Univ, Grad Sch Med, Dept Hematol Oncol & Resp Med, Okayama, Japan
[2] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[3] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan
[4] Okayama Univ, Tsuyama Cent Hosp, Okayama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7624
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7624
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
    Yamamoto, Takaya
    Tsukita, Yoko
    Katagiri, Yu
    Matsushita, Haruo
    Umezawa, Rei
    Ishikawa, Yojiro
    Takahashi, Noriyoshi
    Suzuki, Yu
    Takeda, Kazuya
    Miyauchi, Eisaku
    Saito, Ryota
    Katsuta, Yoshiyuki
    Kadoya, Noriyuki
    Jingu, Keiichi
    BMC CANCER, 2022, 22 (01)
  • [42] Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression
    Genova, C.
    Rijavec, E.
    Rossi, G.
    Biello, F.
    Barletta, G.
    Tagliamento, M.
    Grossi, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Impact of Advantage in Tumor Response on the Correlation Between Progression-Free Survival and Overall Survival: Meta-Analysis of Clinical Trials in Patients with Advanced Non-Small Cell Lung Cancer
    Yoshida, Yosuke
    Kaneko, Masayuki
    Narukawa, Mamoru
    PHARMACEUTICAL MEDICINE, 2021, 35 (02) : 81 - 92
  • [44] Impact of Advantage in Tumor Response on the Correlation Between Progression-Free Survival and Overall Survival: Meta-Analysis of Clinical Trials in Patients with Advanced Non-Small Cell Lung Cancer
    Yosuke Yoshida
    Masayuki Kaneko
    Mamoru Narukawa
    Pharmaceutical Medicine, 2021, 35 : 81 - 92
  • [45] Overall Survival (OS) of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) After Negative Invasive Mediastinal Staging
    Bourdages-Pageau, E.
    Vieira, A.
    Labbe, C.
    Figueroa, P. Ugalde
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2233 - S2234
  • [46] Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
    Camidge, D. R.
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Wilner, K. D.
    Costa, D. B.
    Shapiro, G.
    LoRusso, P.
    Stephenson, P.
    Tang, Y.
    Ruffner, K.
    Clark, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
    Lee, Chee Khoon
    Brown, Chris
    Gralla, Richard J.
    Hirsh, Vera
    Thongprasert, Sumitra
    Tsai, Chun-Ming
    Tan, Eng Huat
    Ho, James Chung-Man
    Chu, Da Tong
    Zaatar, Adel
    Osorio Sanchez, Jemela Anne
    Vu Van Vu
    Au, Joseph Siu Kie
    Inoue, Akira
    Lee, Siow Ming
    Gebski, Val
    Yang, James Chih-Hsin
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (09): : 595 - 605
  • [48] Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC)
    Sidhu, R.
    Rong, A.
    Dahlberg, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Halabi, S.
    Rini, B. I.
    Stadler, W. M.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors.
    Woodford, Rachel
    Zhou, Deborah
    Kok, Peey-Sei
    Lord, Sally
    Marschner, Ian
    Friedlander, Michael
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345